Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review

Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) first-line therapy, has shown good clinical outcomes in non-small cell lung cancer (NSCLC), but some serious adverse events such as cardiotoxicity have also been reported. Here, we present the first...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qianqian, Liu, Haiyang, Yang, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170288/
https://www.ncbi.nlm.nih.gov/pubmed/35677717
http://dx.doi.org/10.3389/fendo.2022.833929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170288/
https://www.ncbi.nlm.nih.gov/pubmed/35677717
http://dx.doi.org/10.3389/fendo.2022.833929

Ejemplares similares